Business
-
United Therapeutics announced that it has been issued a new US patent covering Tyvaso treprostinil inhalation solution for the treatment of pulmonary arterial hypertension and that it has subsequently amended its recently filed suit against Liquidia… Read more . . .
-
Health Canada has issued a Notice of Compliance for Janssen Pharmaceutical’s Spravato esketamine nasal spray for the treatment of major depressive disorder, and the product is now available to Canadian patients, the company said. Spravato… Read more . . .
-
Verona Pharma announced that it has raised approximately $200 million in a private placement, with net proceeds of ~$183 million to be used for Phase 3 development of nebulized ensifentrine for the treatment of COPD.… Read more . . .
-
According to the UK’s Medicines & Healthcare products Regulatory Agency (MHRA), Ferring Pharmaceuticals has recalled multiple batches of Desmospray 0.1 mg/ml desmopressin, Aspire branded desmopressin 0.1 mg/ml, and Octim desmopressin 1.5 mg/ml nasal sprays “due… Read more . . .
-
The United States Patent and Trademark Office has issued US Patent No. 10682414, titled, “Intranasal epinephrine formulations and methods for the treatment of disease,” to ARS Pharmaceuticals, the company said. The patent covers the use… Read more . . .
-
Teva has announced the US launch of the ProAir Digihaler albuterol DPI for the treatment of bronchospasm. The list price for the inhaler will be $146.67. ProAir Digihaler, which includes built-in sensors connected to a mobile app… Read more . . .
-
Inhalation solutions and suspensions manufacturer Nephron Pharmaceuticals has announced plans for a $215 million expansion at its South Carolina, USA facilities, including office, warehouse and vaccine production space. In addition to manufacturing its own products, Nephron also… Read more . . .
-
Optinose announced that it has signed an agreement with Kaleo for co-promotion of Optinose’s Xhance fluticasone propionate nasal spray for the treatment of nasal polyps. Xhance was approved by the FDA for that indication in… Read more . . .
-
Altimmune said that it has signed an agreement with DynPort Vaccine Company regarding Altimmune’s AdCovid intranasal vaccine candidate for COVID-19. The company announced in March 2020 that it had partnered with the University of Alabama Birmingham to… Read more . . .
-
Iconovo announced that BNC Korea has acquired rights to manufacture and market generic versions of Ultibro indacaterol/glycopyrronium and Seebri glycopyrronium DPIs based on Iconovo formulations and the company’s ICOcap device. The deal covers a territory… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden